A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea
A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea
A multi-center, randomized, double-blinded equivalence clinical trial to evaluate efficacy and safety of LipiLou 20 mg versus Lipitor 20 mg in hypercholesterolemic patients with higher risk cardiovascular disease in Korea.
Inclusion Criteria:
Dyslipidemic patients with high-risk cardiovascular disease meeting more than 1 requirement below (LDL-C ≥ 100mg/dL) 1) Coronary artery disease
Aged 20~85 years
Volunteers consented with participating clinical trial and submitted consent paper
Exclusion Criteria:
Experimental examination at screening 1) Active liver disease or more than 2 x ULN of AST/ALT 2) Creatine Kinase > 2 x ULN 3) Creatinine > 2.5mg/dL 4) Triglycerides > 500mg/dL
intervened with stent in coronary artery disease less than 1 year before
Hyper-sensitive or resistant to other HMG-CoA reductase inhibitors, or experienced serious adverse events
Patients taking dyslipidemic treatments within 4 weeks (HMG-CoA reductase inhibitors, fibrates, nicotinic acids or bile acid resins, etc.)
As uncontrolled DM patients, HbA1c≥11% or fasting plasma glucose ≥200mg/dL
DBP > 100mmHg, SBP > 160mmHg
Diagnosed with myopathy
Appear to be a risk of myopathy below
Women pregnant or breast-feeding
Women capable of pregnancy without using contraceptives
contra-indicated medically or mentally, or forbidden legally
Enrolled to other clinical trial within 4 weeks
Impossible to participate clinical trial according to investigator's decision